NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
63304-0046-01 | 63304-0046 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 4, 2023 | In Use | |
64380-0127-02 | 64380-0127 | Cyclosporine | Cyclosporine | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Aug 16, 2022 | In Use | |
70771-1664-08 | 70771-1664 | Isotretinoin | Isotretinoin | 25.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jun 9, 2025 | In Use | |
44278-0025-30 | 44278-0025 | EXEMESTANE | Exemestane | 25.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Nov 22, 2013 | In Use | ||
00832-0595-30 | 00832-0595 | Exemestane | Exemestane | 25.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jul 27, 2017 | In Use | ||
73555-0500-00 | 73555-0500 | Revumenib | Revuforj | 25.0 mg/1 | Chemotherapy | Enzyme Inhibitor | KMT2A | Oral | Nov 15, 2024 | In Use | |
70710-1576-08 | 70710-1576 | Isotretinoin | Isotretinoin | 25.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jun 9, 2025 | In Use | |
59572-0711-01 | 59572-0711 | Luspatercept | REBLOZYL | 25.0 mg/1 | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Subcutaneous | Nov 8, 2019 | In Use | ||
70771-1374-03 | 70771-1374 | Exemestane | Exemestane | 25.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Oct 8, 2018 | In Use | ||
68382-0913-06 | 68382-0913 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
60687-0132-11 | 60687-0132 | Exemestane | Exemestane | 25.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Mar 31, 2015 | Apr 30, 2017 | No Longer Used | |
63629-2056-01 | 63629-2056 | Exemestane | Exemestane | 25.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Dec 19, 2019 | In Use | ||
72603-0329-01 | 72603-0329 | Exemestane | Exemestane | 25.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan 1, 2025 | In Use | ||
63304-0092-86 | 63304-0092 | Sunitinib malate | Sunitinib malate | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec 25, 2019 | In Use | |
47781-0488-01 | 47781-0488 | Lenalidomide | LENALIDOMIDE | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 3, 2022 | In Use | |
51862-0458-47 | 51862-0458 | Cyclosporine | Cyclosporine | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Jul 18, 2016 | In Use | |
70771-1521-03 | 70771-1521 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
50419-0390-01 | 50419-0390 | LAROTRECTINIB | VITRAKVI | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | Oral | Jul 26, 2019 | In Use | |
00310-0625-28 | 00310-0625 | SELUMETINIB | KOSELUGO | 25.0 mg/1 | Chemotherapy | MEK Inhibitor | MEK 1/2 | Oral | Jun 11, 2021 | In Use | |
47781-0488-77 | 47781-0488 | Lenalidomide | LENALIDOMIDE | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 3, 2022 | In Use | |
69097-0516-07 | 69097-0516 | Cyclophosphamide | Cyclophosphamide | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Jan 18, 2019 | In Use | |
68382-0383-06 | 68382-0383 | Exemestane | Exemestane | 25.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Oct 8, 2018 | In Use | ||
69097-0385-81 | 69097-0385 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
00378-5001-93 | 00378-5001 | Exemestane | Exemestane | 25.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Mar 10, 2017 | Apr 30, 2023 | No Longer Used | |
00069-0227-03 | 00069-0227 | Lorlatinib | Lorbrena | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1 | Oral | Jan 3, 2025 | In Use |
Found 11765 results — Export these results